Disruptive technology controls bleeding & leakage during surgery & trauma
“AC5 Surgical Hemostatic Device™ stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision.”
Physicians, industry and patients need a universal sealant for the challenges presented when an opening is created in the body, whether via surgery, trauma, colonoscopy biopsy, device implantation, or in consumer settings. The surgeon must manage and preferably prevent bleeding and leakage, as well as other challenges. Currently available tools to resolving these problems are often inadequate.
Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of bodily substances.
Arch’s products are not yet in human clinical trials, but are progressing in preclinical development. The first product, the AC5 Surgical Hemostatic Device,™ is designed to achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures.
Surgeons would deem the product a “must have” because of its tremendous features, making it very different and far advanced compared to anything else on the market today. AC5™ stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision. Because it is not sticky or glue-like, it is ideal for use in the laparoscopic setting – a challenge for much of the competition. Furthermore, it is transparent, enabling a surgeon to operate through it in order to prophylactically stop bleeding as it starts – we call this Crystal Clear Surgery™. Importantly, time to hemostasis (TTH) for AC5™ is typically measured in seconds, rather than the many minutes as required by much of the competition.
In preclinical tests, AC5™ has been simple, effective, and versatile. To date, biocompatibility has been excellent and healing of tissue treated with the device has been normal.
Co-founding and inventing scientist, Rutledge Ellis-Behnke, performs research on nanomedicine, tissue regeneration, neurocognitive topics, and a range of related areas. Examples of peer-reviewed articles are listed below.
- Ellis-Behnke RG, Liang YX, Tay DKC, Kau PWF, Schneider GE, Zhang S, Wu W and So KF. (2006) Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2: 207-15.
- Comments in Science, JAMA, Nature Biotechnology, Nature nanomedicine, etc.
- Ellis-Behnke RG. (2011) At the nanoscale: nanohemostat, a new class of hemostatic agent. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 3: 70-8.
- Sang LYH, Liang YX, Li Y, Wong, WM, Tay DKC, So KF, Ellis-Behnke RG, Wu WT, Cheung RTF. (2014) A self-assembling nanomaterial reduces acute brain injury and enhances functional recovery in a rat model of intracerebral hemorrhage. Nanomedicine.